CONTINEUM THERAPEUTICS INC-A
CTNMNASDAQTrading Snapshot
- Day Range
- $9.13 – $9.87
- 52-Week Range
- $6.73 – $17.79
- Volume (shares)
- 566,921
- Avg Volume (shares)
- —
- Shares Outstanding
- 33.0M
- Next Earnings
- 2026-11-11
Fundamentals Snapshot
- Annual Revenue
- —
- Last Q Revenue
- —
- P/E Ratio
- -5.4
- P/S Ratio
- 0.0x
- EPS (TTM)
- $-1.54
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +19.4%
CONTINEUM THERAPEUTICS INC-A
CTNM
StockOtter · stockotter.spaceAbout CONTINEUM THERAPEUTICS INC-A
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The company’s lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and chronic pain. It also develops PIPE-307, a novel, small-molecule inhibitor of the muscarinic type 1 receptor for depression and relapse-remitting multiple sclerosis. The company was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. Contineum Therapeutics, Inc. was incorporated in 2009 and is based in San Diego, California.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Latest News & Updates
All You Need to Know About Contineum Therapeutics, Inc. (CTNM) Rating Upgrade to Buy
Contineum Therapeutics, Inc. (CTNM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Why Is Contineum Therapeutics Stock Falling Monday?
Contineum Therapeutics Inc. (NASDAQ:CTNM) stock plunged Monday following mixed Phase 3 trial results for Bristol Myers Squibb & Co.'s (NYSE:BMY) competing lung disease drug, admilparant.
48,108 Contineum Therapeutics, Inc. $CTNM Shares Sold by Squarepoint Ops LLC
Squarepoint Ops LLC lessened its position in shares of Contineum Therapeutics, Inc. (NASDAQ: CTNM) by 80.4% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchan
Contineum Therapeutics (NASDAQ:CTNM) Trading Down 9.9% After Analyst Downgrade
Shares of Contineum Therapeutics, Inc. (NASDAQ: CTNM - Get Free Report) dropped 9.9% during mid-day trading on Tuesday after JonesTrading lowered their price target on the stock from $26.00 to $24.00. JonesTrading curren
Johnson & Johnson Partner Contineum Slides as Depression Drug Fails
Contineum Therapeutics, Inc. (NASDAQ:CTNM) shares are trading lower on Tuesday as Phase 2 results from a key study disappoint.
Contineum Therapeutics Reports Phase 2 Results for JNJ-5120/PIPE-307 for the Treatment of Major Depressive Disorder
SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated small molecule therapies for inflammatory and fibro